This is a limited company view. Sign up for a Free Trial to see everything.

Valderm develops second generation anthracycline valrubicin for the innovative topical treatment of hyperproliferative skin diseases.

Biotechnology

Overview

Location

Lyngby

Founded

Employees

0

Stage

Series A

Total funding

$3M

Last funding

11 years ago

Acquisitions

0

Growth score

13

Mindshare score

13

Scoring

Deals

$3.4M Series A

Seed Capital

Aug 17, 2007

Employee Growth

Use Valderm's historical employee count to better understand their growth and spending over time.

Unlock with a Free Trial

Mobile

Use Valderm's mobile downloads and app ranks to evaluate the performance of their mobile apps.

Unlock with a Free Trial

Gain context with Mattermark Salesforce Enrichment

Find out how

Notes